Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

in castrate resistant prostate cancer in 2010, and a third Phase III trial in non-small cell lung cancer in early 2011. OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals ( ISIS), to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities, the potential benefits of our product candidates, our key 2010 objectives, expectations regarding accrual of clinical trials and timing of release of results of studies, and our anticipated future expenses, revenues, reimbursements, capital and sufficiency of capital. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a num
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... InSphero AG , ... organotypic 3D cell culture models, announced today that its patented GravityPLUS™ Hanging ... now available for purchase exclusively through PerkinElmer.     , InSphero will now broaden global ...
(Date:8/5/2015)... (PRWEB) , ... August 05, 2015 , ... ... to aid the transition from legacy tubes, with 2D barcode labels on the ... decodes 100 legacy tube 2D barcodes in 1 second, using FluidX’s IntelliCode software, ...
(Date:8/5/2015)... ... August 05, 2015 , ... MTI-GlobalStem, a leading supplier ... an updated corporate identity, including new company name, logo and website. GlobalStem was ... company moved into a new, joint facility in 2014 to bring the two ...
(Date:8/4/2015)... ... August 05, 2015 , ... Spirax Sarco , Inc. ... line.” The handbook provides a complete range of information needed to evaluate ... standard product offering into an easy-to-navigate single edition,” says Dawn Dukes, Public Relations ...
Breaking Biology Technology:InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 2InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 3RURO Announces FreezerPro® 7 Integration with Top-down 2D barcode scanners by FluidX 2MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3Spirax Sarco releases Product Handbook 2
... Entire Project Information, CAMBRIDGE, England and ... plc (LSE: AU. or AU.L), a,global leader ... that Extract Technology, a leading supplier of ... markets, has,implemented its Meridio records management solution ...
... PXS; Nasdaq: PXSL) today announced the appointment of ... of directors., Mr Delaat has 35 years ... the managing director of the Australian,subsidiary of Merck ... until his recent,retirement., During his career Mr ...
... has developed a technique that controls the number of ... considered impossible for the past two decades. , Led ... potassium atoms onto the surface of a piece of ... continuously manipulate the number of electrons on ultra-thin layers ...
Cached Biology Technology:Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 2Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 3Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 4New Pharmaxis Board Appointment 2UBC physicists develop 'impossible' technique to study and develop superconductors 2
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... games, pioneering gene therapies and new medical devices are ... from the Department of Health and the Wellcome Trust. ... Health Innovation Challenge Fund, which was set up in ... with potential clinical application in the NHS within a ...
... University of Nottingham have opened the way for more ... infections by proving a long-held theory about how bacteria ... School of Molecular Medical Sciences have shown for the ... method, a process called ,quorum sensing, directly depends on ...
... PITTSBURGH, May 17, 2012 A change in the formulation ... may make it safer to use in the rectum, suggests ... of Antimicrobial Chemotherapy. In laboratory tests of rectal ... the reformulated gel was less harmful to the lining of ...
Cached Biology News:NHS set to benefit from UK-led technologies 2NHS set to benefit from UK-led technologies 3Fighting bacteria's strength in numbers 2Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use 2Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use 3
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
... in Refrigerated Vapor Trap Models RVT100, RVT400, ... Models UVS400, UVS400A and UVS800DDA., A non-corrosive, ... use for temperatures ranging from -105 to ... stability and does not evaporate. Far superior ...
Acetate Plate Sealers 100/Box...
... of proteomics demands the detection of very ... of the AXIMA-CFRplus with improved resolution (20,000) ... provides increased confidence in protein identification. The ... sensitivity, automated sample target handling and the ...
Biology Products: